Brenzavvy vs Jardiance: Key Comparisons for Diabetes

Introduction to Brenzavvy and Jardiance

When navigating a new type 2 diabetes diagnosis or adjusting an existing treatment plan, you may encounter the class of medications known as SGLT2 inhibitors. Brenzavvy vs Jardiance is a common comparison, as both belong to this category, but they differ in their clinical evidence, approval timelines, and the depth of cardiovascular outcome data supporting their use.

SGLT2 inhibitors work by blocking a protein in the kidneys called sodium-glucose cotransporter 2. This protein normally reabsorbs glucose from the urine back into the bloodstream. By inhibiting it, these medications allow excess glucose to leave the body through urine, which can lower blood sugar levels without directly stimulating insulin production. This mechanism makes them distinct from medications like metformin or GLP-1 receptor agonists.

Both Brenzavvy and Jardiance are taken as once-daily oral tablets and are typically used alongside diet and exercise. They may be prescribed alone or in combination with other diabetes medications, depending on individual treatment goals and medical history. For a broader look at medication options, see our guide on Brenzavvy vs Jardiance: Comparing Diabetes Medications.

The choice between these two agents often comes down to factors like cardiovascular risk profile, insurance coverage, side-effect tolerance, and the strength of clinical evidence for outcomes that matter to you and your provider. Research comparing SGLT2 inhibitors has shown variation in their effects on cardiovascular mortality, heart failure hospitalization, and other endpoints. Understanding these distinctions can help you ask informed questions at your next appointment and clarify what to expect from your medication.

In the sections that follow, we'll compare the clinical efficacy, safety profiles, and cost considerations for Brenzavvy and Jardiance, drawing on peer-reviewed trial data and manufacturer guidance to give you a clear, editorial perspective on how these medications stack up.

How Do Brenzavvy vs Jardiance Compare in Effectiveness?

Both Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) belong to the SGLT2 inhibitor class, meaning they work by blocking glucose reabsorption in the kidneys to lower blood sugar. While they share the same mechanism, their clinical trial results show different patterns in cardiovascular outcomes and overall efficacy.

Cardiovascular Outcomes: What the Trials Show

Jardiance has been studied extensively in large cardiovascular outcome trials. The EMPA-REG OUTCOME trial demonstrated that participants taking empagliflozin had significantly lower rates of major adverse cardiovascular events (3P-MACE) and death from all causes compared to placebo. This trial included over 7,000 patients with type 2 diabetes and established cardiovascular disease, making it one of the landmark studies for SGLT2 inhibitors.

Brenzavvy, as a newer medication in the SGLT2 inhibitor class, does not yet have the same depth of long-term cardiovascular outcome data. Comparative analyses of SGLT2 inhibitors show variability across the class — canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin all demonstrate efficacy against placebo for outcomes including all-cause mortality and hospitalization for heart failure, but the magnitude of benefit differs between agents.

Blood Sugar Control and A1C Reduction

Both medications reduce A1C by helping the body eliminate excess glucose through urine. The degree of A1C reduction typically ranges from 0.5% to 1% when added to other diabetes medications, though individual response varies based on baseline glucose levels, kidney function, and other factors. If you're wondering how these reductions translate to daily glucose readings, A1C conversion charts can help you understand what your number means.

Heart Failure and Kidney Protection

The DECLARE-TIMI 58 trial, which studied dapagliflozin (another SGLT2 inhibitor), showed no significant difference in 3P-MACE but demonstrated reduced cardiovascular mortality and lower rates of hospitalization due to heart failure. These findings highlight that not all SGLT2 inhibitors perform identically across all cardiovascular endpoints.

Jardiance has FDA approval for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, as well as for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. Brenzavvy's labeling currently focuses on glycemic control and does not carry these additional cardiovascular indications.

Comparing Efficacy Across the Class

When comparing SGLT2 inhibitors head-to-head, the differences in trial populations, baseline risk, and study design make direct comparisons challenging. The CANVAS Program, which studied canagliflozin, showed a reduction in 3P-MACE but no significant difference in all-cause mortality between treatment and placebo groups. This mixed pattern across trials suggests that while the class shares a common mechanism, individual agents may offer different risk-benefit profiles depending on a patient's specific cardiovascular and metabolic status.

For newly diagnosed patients or those adjusting their regimen, understanding these nuances matters less than knowing that your care team will select an SGLT2 inhibitor based on your kidney function, cardiovascular history, insurance coverage, and treatment goals. The "best" medication is the one that fits your clinical picture and that you can access consistently.

Side Effects and Safety

Both Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) belong to the SGLT2 inhibitor class, which means they share a similar mechanism and, consequently, a similar side-effect profile. Understanding what to watch for can help you and your care team manage these medications safely.

Common Side Effects Across SGLT2 Inhibitors

Because SGLT2 inhibitors increase glucose in the urine, they create an environment that can encourage infections. In clinical trials of dapagliflozin (another SGLT2 inhibitor with a comparable profile), genital infections were notably more common than in placebo groups. Male genital infections occurred in 0.9% of patients taking the SGLT2 inhibitor compared to 0.1% on placebo, while female genital infections were reported in 68.8% of those on the medication versus 17.5% on placebo. Both findings were statistically significant. While these numbers come from dapagliflozin trials, the mechanism is shared across the class, so similar patterns are expected with Brenzavvy and Jardiance.

Urinary tract infections are also more common with SGLT2 inhibitors, though the increase is generally modest. If you notice symptoms like burning during urination, increased urgency, or cloudy urine, contact your provider promptly.

Serious Adverse Events and Safety Signals

Serious adverse events in SGLT2 inhibitor trials have been lower or comparable to placebo in many cases. In the dapagliflozin trial, serious adverse events occurred in 34.1% of patients on the medication compared to 36.2% on placebo, a statistically significant difference favoring the SGLT2 inhibitor. This suggests that while side effects exist, the overall safety profile is manageable when patients are appropriately selected and monitored.

Hypoglycemia (low blood sugar) is generally uncommon with SGLT2 inhibitors when used alone, because they do not directly stimulate insulin release. In the dapagliflozin trial, hypoglycemia occurred in 0.7% of patients on the medication versus 1.0% on placebo. However, if you are taking an SGLT2 inhibitor alongside insulin or a sulfonylurea, your risk of low blood sugar increases, and your care team may need to adjust those other medications.

Other safety considerations include a modest risk of dehydration and low blood pressure, particularly when starting the medication or during illness. Your care team may recommend staying well-hydrated and monitoring for dizziness or lightheadedness, especially if you also take diuretics or blood-pressure medications. For more guidance on managing blood sugar and medication adjustments, see our article on how to lower A1C naturally.

Who Should Use Caution

SGLT2 inhibitors are not appropriate for everyone. They are not recommended for people with severe kidney impairment (though the threshold varies by medication), those with a history of recurrent genital or urinary infections, or individuals at high risk for dehydration. If you have a history of DKA, discuss this carefully with your provider before starting an SGLT2 inhibitor.

Your care team will assess your kidney function, infection history, and other medications before prescribing Brenzavvy or Jardiance, and they will monitor you regularly to catch any emerging issues early.

Cost Analysis

The price of an SGLT2 inhibitor can vary significantly depending on insurance coverage, pharmacy benefit design, and manufacturer assistance programs. Both Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) are brand-name medications without generic equivalents currently available in the United States, which typically means higher out-of-pocket costs for patients without comprehensive prescription coverage.

List Price and Insurance Coverage

List prices for SGLT2 inhibitors generally fall in a similar range, though the actual amount a patient pays depends on their insurance formulary tier and whether the medication requires prior authorization. Some insurance plans may place one SGLT2 inhibitor on a preferred tier while requiring step therapy or higher copays for another. Patients should confirm with their insurance provider which medication is covered at the lowest tier and whether any prior authorization is required before filling a prescription.

Manufacturer copay cards and patient assistance programs are available for both medications, which can reduce out-of-pocket costs for eligible patients. These programs typically have income and insurance eligibility requirements, and coverage may not apply to patients with government insurance such as Medicare or Medicaid.

Real-World Usage Patterns

Data from large patient databases show differences in prescribing volume between SGLT2 inhibitors. In one analysis of adult male patients with type 2 diabetes, approximately 388,893 received canagliflozin (another SGLT2 inhibitor) compared to 657,134 who received empagliflozin (Jardiance). While this comparison does not directly include Brenzavvy, it illustrates that prescribing patterns can vary based on factors including formulary placement, clinical trial data availability, and prescriber familiarity with specific agents.

Comparing Costs Without Direct Trials

One challenge in evaluating SGLT2 inhibitors is the absence of head-to-head cost-effectiveness studies. There is currently no randomized controlled trial or retrospective head-to-head comparison of any available SGLT2 inhibitors that directly assesses cost per outcome achieved. This means that cost comparisons rely on list prices, insurance tier placement, and indirect comparisons of clinical trial outcomes rather than direct economic evaluations.

For patients navigating medication costs, the most practical approach is to check both medications with your insurance plan and pharmacy, review available manufacturer assistance programs, and discuss with your prescriber whether one option offers a cost advantage without compromising clinical goals. If cost is a barrier, some patients may also explore other medication options or lifestyle strategies to manage blood sugar, though this decision should always be made in consultation with your care team.

Conclusion

Both Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) belong to the SGLT2 inhibitor class and help lower blood sugar by prompting the kidneys to remove excess glucose through urine. While they share a mechanism, the evidence base for cardiovascular and mortality outcomes differs significantly between the two medications.

Empagliflozin Shows Stronger Cardiovascular Evidence

Jardiance has been studied extensively in large cardiovascular outcome trials and demonstrated reductions in all-cause mortality and cardiovascular mortality compared to placebo and other SGLT2 inhibitors. Network meta-analyses consistently position empagliflozin as more effective in reducing cardiovascular death than canagliflozin, dapagliflozin, and placebo. Brenzavvy, as a newer agent, does not yet have comparable long-term cardiovascular outcome data published in peer-reviewed trials.

What This Means for Your Decision

If cardiovascular risk reduction is a priority in your diabetes management plan, Jardiance carries a more established evidence profile for mortality benefits. If cost or insurance coverage makes Brenzavvy more accessible, it remains a reasonable option for glucose control, though you and your care team will need to weigh the trade-off in cardiovascular outcome data. Both medications carry similar risks for genital yeast infections and urinary tract infections, and both require monitoring for ketoacidosis and kidney function.

Your prescribing decision should account for your individual cardiovascular risk, kidney function, insurance formulary, and how the medication fits with the rest of your regimen. The right medication is the one that matches your clinical profile and that you can access consistently. For detailed guidance on how lifestyle changes complement medication in lowering A1C, see our natural A1C reduction strategies.

Confirm your medication choice with your endocrinologist or primary care provider — they will integrate your lab results, comorbidities, and coverage realities into a recommendation tailored to your situation.

FAQ

What is the main difference between Brenzavvy vs Jardiance?

Brenzavvy vs Jardiance differs primarily in the depth of cardiovascular outcome data. Jardiance has extensive trial evidence showing reductions in cardiovascular and all-cause mortality, while Brenzavvy is a newer agent without comparable long-term cardiovascular outcome studies.

Which SGLT2 inhibitor is more effective for heart protection?

Jardiance (empagliflozin) has demonstrated stronger cardiovascular benefits in clinical trials, including reductions in cardiovascular death and heart failure hospitalization. Network meta-analyses position empagliflozin as more effective for cardiovascular outcomes than other SGLT2 inhibitors.

Are Brenzavvy and Jardiance safe for people with kidney disease?

Both medications require adequate kidney function to work effectively for glucose lowering. Your care team will assess your eGFR before prescribing either medication. Some cardiovascular and kidney-protective benefits may persist at lower eGFR levels, but this varies by individual.

Do Brenzavvy and Jardiance cause the same side effects?

Yes, as members of the SGLT2 inhibitor class, Brenzavvy vs Jardiance share a similar side-effect profile. Both increase the risk of genital yeast infections and urinary tract infections due to increased glucose in the urine. Both also carry a rare risk of diabetic ketoacidosis.

Which is more affordable: Brenzavvy or Jardiance?

Cost depends on your insurance formulary tier and available manufacturer assistance programs. Both are brand-name medications without generic equivalents. Check with your pharmacy to compare actual copay amounts for Brenzavvy vs Jardiance under your specific plan.